Strides Pharma Science Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Price Movement and Market Context

On 29 June 2026, Strides Pharma’s share price closed at ₹1,083.15, down 2.49% from the previous close of ₹1,110.80. The stock traded within a range of ₹1,073.50 to ₹1,118.60 during the day, remaining below its 52-week high of ₹1,231.45 but comfortably above the 52-week low of ₹769.60. This recent price dip contrasts with the broader market, as the Sensex showed a modest gain of 0.80% over the past month, while Strides Pharma declined by 8.91% in the same period.

Technical Trend Shift: From Bullish to Mildly Bullish

The overall technical trend for Strides Pharma has shifted from bullish to mildly bullish, signalling a tempering of upward momentum. This subtle change suggests that while the stock retains some positive momentum, caution is warranted as the strength of the trend appears to be moderating.

MACD Analysis

The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On a weekly basis, the MACD is mildly bearish, indicating that short-term momentum may be weakening. However, the monthly MACD remains bullish, suggesting that the longer-term trend still favours upward movement. This divergence between weekly and monthly MACD readings highlights the importance of timeframe in technical analysis and suggests that short-term traders may face more volatility compared to long-term investors.

RSI Signals

The Relative Strength Index (RSI) adds further complexity. The weekly RSI currently shows no clear signal, implying a neutral momentum in the short term. Conversely, the monthly RSI is bearish, indicating that the stock may be overbought or facing downward pressure over the longer horizon. This bearish monthly RSI aligns with the weekly MACD’s mild bearishness, reinforcing the notion of caution for investors looking at shorter to medium-term horizons.

Bollinger Bands and Moving Averages

Bollinger Bands on both weekly and monthly charts are mildly bullish, suggesting that price volatility is contained within an upward trending channel. This is a positive sign for price stability and potential continuation of gains. Daily moving averages also support a mildly bullish stance, indicating that recent price action is above key average price levels, which often act as support in technical analysis.

KST and Dow Theory Perspectives

The Know Sure Thing (KST) indicator is bullish on a weekly basis but mildly bearish monthly, echoing the mixed signals seen in MACD and RSI. Meanwhile, Dow Theory assessments are mildly bullish weekly and bullish monthly, providing some reassurance that the broader trend remains positive despite short-term fluctuations.

On-Balance Volume (OBV) Insights

OBV readings are mildly bullish weekly and bullish monthly, indicating that volume trends support price gains over the longer term. This suggests that accumulation by investors is ongoing, which could underpin future price strength if sustained.

Comparative Returns and Market Performance

Strides Pharma has delivered impressive returns over multiple timeframes compared to the Sensex benchmark. Year-to-date, the stock has gained 20.04%, while the Sensex declined by 9.53%. Over one year, Strides Pharma’s return stands at 21.68%, outperforming the Sensex’s negative 6.83%. The long-term performance is even more striking, with a three-year return of 446.17% versus the Sensex’s 22.42%, and a five-year return of 197.20% compared to the Sensex’s 45.68%. However, over a ten-year horizon, the Sensex’s 192.07% outpaces Strides Pharma’s 113.36%, reflecting the cyclical nature of the pharmaceutical sector and company-specific factors.

Market Capitalisation and Mojo Ratings

Strides Pharma is classified as a small-cap stock with a Mojo Score of 56.0, reflecting a Hold rating. This is an upgrade from a previous Sell rating issued on 6 April 2026, signalling improved confidence in the company’s prospects. The Mojo Grade upgrade suggests that while the stock is not yet a strong buy, it has moved into a more favourable technical and fundamental position, meriting attention from investors seeking growth within the Pharmaceuticals & Biotechnology sector.

Investment Implications and Outlook

The mixed technical signals for Strides Pharma Science Ltd indicate a period of consolidation and cautious optimism. The mildly bullish trend combined with some bearish indicators suggests that investors should monitor key support and resistance levels closely. The stock’s current price near ₹1,083 is below its recent high but well above its 52-week low, offering a potential entry point for those with a medium to long-term horizon.

Given the divergence in weekly and monthly technical indicators, short-term traders may experience volatility, while long-term investors could benefit from the underlying bullish momentum supported by volume and moving averages. The upgrade to a Hold rating by MarketsMOJO further supports a watchful stance rather than aggressive accumulation at this stage.

Conclusion

Strides Pharma Science Ltd’s recent technical parameter changes reflect a nuanced shift in price momentum, with a blend of mildly bullish and bearish signals across various indicators. While the stock’s short-term outlook appears cautious due to weekly MACD and RSI readings, the longer-term monthly indicators and volume trends remain supportive of a positive trajectory. The upgrade to a Hold rating by MarketsMOJO underscores this balanced view, suggesting that investors should consider the stock as a watchlist candidate with potential for growth, especially given its strong historical returns relative to the Sensex.

Investors are advised to keep a close eye on evolving technical signals and broader market conditions, as these will be critical in determining whether Strides Pharma can sustain its upward momentum or face further consolidation in the near term.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →